Posted by Michael Wonder on 27 May 2021
Lantheus receives U.S. FDA approval of Pylarify (piflufolastat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer
27 May 2021 - Pylarify will be available immediately to imaging centres in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U.S. by year end.
Lantheus announced today that the U.S. FDA has approved Pylarify an F 18-labeled prostate-specific membrane antigen targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer.
